CAMBRIDGE, Mass. – November 26, 2024 -- Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Jeff Jonas, MD will retire from the Company’s Board of Directors as of December 1, 2024. The Company has initiated a search for a new director. Dr. Jonas was CEO at Sage from 2013 to 2020, Chief Innovation Officer from 2020 to 2022, and has served on the Board since 2013.

Dr. Jonas is currently a Partner at Cure Ventures, bringing over two decades of experience in R&D leadership and CNS drug discovery to his role. Before joining Cure, Dr. Jonas was CEO, President, and Director at ABIO-X, a life science incubator focused on transformative medicines. Prior to ABIO-X and Sage Therapeutics, he was President of the Regenerative Medicine Division at Shire Pharmaceuticals, where he directed strategy for marketed products and new pipeline development. Earlier in his career, Dr. Jonas was EVP at ISIS (Ionis) Pharmaceuticals and held senior roles at Forest Laboratories and Upjohn.

Dr. Jonas has authored over 300 peer-reviewed publications, chapters, and presentations; and holds multiple patents. He earned a BA from Amherst College, an MD from Harvard Medical School, and completed a psychiatry residency at Harvard, where he was Chief Resident of Psychopharmacology at McLean Hospital. He currently serves on the board of Generation Bio and is Chairman of Noema Therapeutics and Kenai Therapeutics.